Unknown

Dataset Information

0

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

ABSTRACT: KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.

SUBMITTER: Poirel L 

PROVIDER: S-EPMC7526841 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

Poirel Laurent L   Vuillemin Xavier X   Juhas Mario M   Masseron Amandine A   Bechtel-Grosch Ursina U   Tiziani Simon S   Mancini Stefano S   Nordmann Patrice P  

Antimicrobial agents and chemotherapy 20200722 8

KPC-50 is a KPC-3 variant identified from a <i>Klebsiella pneumoniae</i> clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity. ...[more]

Similar Datasets

Unknown Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.
| S-EPMC6879233 | biostudies-literature
Unknown KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.
| S-EPMC7927837 | biostudies-literature
Unknown Impact of anticancer chemotherapy on the extension of beta-lactamase spectrum: an example with KPC-type carbapenemase activity towards ceftazidime-avibactam.
| S-EPMC6969056 | biostudies-literature
Unknown Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in <i>Citrobacter koseri</i> Following Ceftazidime-Avibactam Treatment.
| S-EPMC9251512 | biostudies-literature
Unknown Emergence of a KPC-90 Variant that Confers Resistance to Ceftazidime-Avibactam in an ST463 Carbapenem-Resistant Pseudomonas aeruginosa Strain.
| S-EPMC8754116 | biostudies-literature
Unknown Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
| S-EPMC6761506 | biostudies-literature
Unknown <i>In vivo</i> Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible <i>Klebsiella pneumoniae</i> Isolate With KPC-33 Carbapenemase.
| S-EPMC8496447 | biostudies-literature
Unknown Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from ?-Lactamase Protein Engineering.
| S-EPMC5666153 | biostudies-literature
Unknown Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing <i>Klebsiella pneumoniae</i>.
| S-EPMC8567916 | biostudies-literature
Unknown Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
| S-EPMC7179312 | biostudies-literature